黄金城集团

至今,GenScript的服务及产品已被Cell, Nature, Science, PNAS等1300多家生物医药类杂志引用近万次,处于行业领先水平。NIH、哈佛、耶鲁、斯坦福、普林斯顿、杜克大学等约400家全球著名机构使用GenScript的基因合成、多肽服务、抗体服务和蛋白服务等成功地发表科研成果,再次证明GenScript 有能力帮助业内科学家Make research easy.

ARTEMIS: A Novel Mass-SpecPlatform for HLA-Restricted Self and Disease-AssociatedPeptide Discovery

Frontiers in Immunology. 2021-04; 
Kathryn A K Finton , Mi-Youn Brusniak , Lisa A Jones, Chenwei Lin , Andrew J Fioré-Gartland, Chance Brock, Philip R Gafken , Roland K Strong
Products/Services Used Details Operation
Gene Synthesis cDNAs encoding SCDs and target proteins were codon optimized for human cells (Genscript), synthesized (Genscript), and subcloned into optimized lentiviral vectors (22) incorporating either mCherry (SCD) or GFP (target protein) fluorescent reporter proteins THE HIS mAb (GenScript, catalogue number A00612) Get A Quote
PCR Cloning and Subcloning Get A Quote

摘要

Conventional immunoprecipitation/mass spectroscopy identification of HLA-restricted peptides remains the purview of specializing laboratories, due to the complexity of the methodology, and requires computational post-analysis to assign peptides to individual alleles when using pan-HLA antibodies. We have addressed these limitations with ARTEMIS: a simple, robust, and flexible platform for peptide discovery across ligandomes, optionally including specific proteins-of-interest, that combines novel, secreted HLA-I discovery reagents spanning multiple alleles, optimized lentiviral transduction, and streamlined affinity-tag purification to improve upon conventional methods. This platform fills a middle ground betwee... More

关键词

MHC class I; immunotherapy; ligandome analysis; mass spectrometry; peptide-HLA complex.